PNKD

PNKD (MR-1) is the gene whose mutation causes autosomal dominant non-kinesiogenic paroxysmal dyskinesia, originally mapped to chromosome 2q31-36 by family linkage analysis (PMID:8659517). The gene produces alternatively spliced isoforms with distinct subcellular fates: the long and short isoforms (MR-1L/MR-1S) carry a 39-amino-acid mitochondrial targeting sequence (MTS) that directs import into the inner mitochondrial membrane where it is cleaved, while the mutation-free MR-1M isoform localizes to Golgi, ER, and plasma membrane (PMID:19124534). All identified disease mutations (A7V, A9V, A33P) fall within this MTS; rather than altering mature protein function, the mutations render the N-terminal cleavage site resistant to processing and accelerate degradation of the protein, lowering cortical PNKD-L levels in mutant mice (PMID:19124534, PMID:21487022). PNKD-L is homologous to the metallo-beta-lactamase superfamily but lacks glyoxalase II activity; nonetheless loss of PNKD reduces cellular glutathione, linking it to redox homeostasis (PMID:21487022). At the synapse, PNKD-L self-oligomerizes and binds the active zone scaffold RIMS1α, and a loss-of-function PNKD variant co-segregates with Tourette Disorder (PMID:28894297). Independently, MR-1 interacts with sarcomeric proteins (MLC2, myomesin 1, beta-enolase) and drives cell proliferation, migration, and adhesion through MLC2/FAK/Akt phosphorylation and stress fiber formation (PMID:15188056, PMID:18948272).

1. 1996 Medium

   Establishing the chromosomal locus for familial paroxysmal dyskinesia was the first step toward identifying the causative gene.

   Evidence Linkage analysis in a segregating family mapping the disorder to 2q31-36 (LOD 4.64)

   PMID:8659517

   Open questions at the time

   • Did not identify the gene or causal variant
   • No molecular function implied
2. 2004 Medium

   Identifying MR-1 binding partners gave the first clue to a molecular function, placing it in contact with sarcomeric machinery.

   Evidence Yeast two-hybrid and in vitro binding assays in skeletal muscle showing interaction with MLC2, myomesin 1, and beta-enolase

   PMID:15188056

   Open questions at the time

   • Interactions not validated in neurons or in vivo
   • No connection to the dyskinesia phenotype established
3. 2008 Medium

   Functional assays defined a signaling role for MR-1, showing it actively drives cytoskeletal remodeling and cell motility rather than acting passively.

   Evidence siRNA knockdown and overexpression in HepG2 cells with phospho-Western blots, pharmacological inhibitors, and xenograft assays linking MR-1 to MLC2/FAK/Akt phosphorylation and stress fibers

   PMID:18948272

   Open questions at the time

   • Mechanism by which MR-1 activates these kinases unknown
   • Relevance to neuronal disease unclear
4. 2009 High

   Resolving isoform-specific localization showed that disease mutations cluster in a mitochondrial targeting sequence, reframing pathogenesis around the MTS rather than the mature protein.

   Evidence Subcellular fractionation, live fluorescence imaging, and import assays of MR-1 isoforms plus mutation identification in a new patient

   PMID:19124534

   Open questions at the time

   • No difference in import efficiency between wild-type and mutant left the toxic mechanism undefined
   • Mitochondrial function consequences not measured
5. 2011 High

   Mechanistic dissection showed mutations block N-terminal cleavage and destabilize PNKD-L, and that PNKD loss lowers glutathione, tying the protein to redox balance.

   Evidence In vitro cleavage and protein-stability assays, transgenic and knockout mouse cortex biochemistry, glyoxalase II enzymatic assay, and glutathione measurement

   PMID:21487022

   Open questions at the time

   • The enzymatic/biochemical activity of PNKD-L remains unidentified despite metallo-beta-lactamase homology
   • How reduced glutathione produces dyskinesia is unresolved
6. 2017 Medium

   Demonstrating PNKD-L oligomerization and binding to the active zone scaffold RIMS1α connected the protein to synaptic machinery and broadened its disease association.

   Evidence Co-immunoprecipitation and Western blot in iPSC-derived neurons, plus whole exome sequencing of a Tourette Disorder family

   PMID:28894297

   Open questions at the time

   • Co-IP not reciprocally validated or reconstituted
   • Functional consequence of the RIMS1α interaction at the synapse not tested

• The catalytic activity of PNKD-L and the mechanism linking MTS cleavage, glutathione homeostasis, and synaptic dysfunction to paroxysmal dyskinesia remain unresolved.
• No demonstrated enzymatic substrate despite metallo-beta-lactamase homology
• Causal chain from protein destabilization to episodic movement disorder not established